AG
NBIX icon

Algert Global’s Neurocrine Biosciences NBIX Stock Holding History

Algert Global’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.63M Buy
19,970
+10
+0.1% +$1.33K 0.04% 638
2025
Q4 		$2.83M Buy
19,960
+17,590
+742% +$2.55M 0.04% 617
2025
Q3 		$333K Buy
+2,370
New +$321K 0.01% 981
2025
Q2 		– Sell
-11,676
Closed -$1.29M – 1288
2025
Q1 		$1.29M Sell
11,676
-22,490
-66% -$2.85M 0.03% 721
2024
Q4 		$4.66M Buy
34,166
+15,800
+86% +$1.95M 0.11% 306
2024
Q3 		$2.12M Buy
+18,366
New +$2.52M 0.06% 531
2024
Q2 		– Sell
-2,042
Closed -$282K – 1565
2024
Q1 		$282K Sell
2,042
-2,140
-51% -$292K 0.01% 903
2023
Q4 		$551K Buy
4,182
+2,220
+113% +$256K 0.02% 793
2023
Q3 		$221K Sell
1,962
-15,244
-89% -$1.61M 0.01% 951
2023
Q2 		$1.62M Buy
+17,206
New +$1.68M 0.07% 468

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Algert Global's NBIX Position: Q1 2026 in Review

Algert Global increased its Neurocrine Biosciences (NBIX) stake by 0.05% in Q1 2026, buying an estimated $1.33K and bringing the position to 19,970 shares worth $2.63M. The position accounts for 0.04% of the portfolio, ranked #638.

Algert Global first reported a position in NBIX in Q2 2023 and has held it in 10 quarters since. The position peaked at $4.66M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Algert Global held 19,970 shares of Neurocrine Biosciences worth $2.63M as of Q1 2026.
  • Algert Global bought 10 Neurocrine Biosciences shares in Q1 2026, an estimated $1.33K.
  • Neurocrine Biosciences made up 0.04% of Algert Global's portfolio in Q1 2026, its #638 holding.
  • Algert Global first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 10 quarters since.
  • Algert Global's Neurocrine Biosciences position peaked at $4.66M in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.